文献速递淋巴瘤

B细胞幼淋巴细胞白血病遗传特征:MYC与TP53预后模型

Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53.
PubMed 文献 · Blood · 2019-01-01

该研究对34例B-PLL患者进行细胞遗传学和分子学评估,发现多数患者存在复杂核型,MYC异常和del17p常见,并据此提出3个细胞遗传学风险组,提示靶向MYC可能为治疗选择。

要点

  • B-PLL常见复杂核型(73%)和高复杂核型(45%)。
  • MYC异常见于76%患者,del17p见于38%。
  • 基于MYC异常和del17p的3组风险模型与预后显著相关(P = .0006)。

核心结论

  • 细胞遗传学分析是B-PLL有用的诊断和预后工具。
  • 靶向MYC可能是B-PLL的有用治疗选择。

研究设计与样本

  • 对34例B-PLL患者进行细胞遗传学和分子学评估(包括全外显子测序)。

主要发现

  • 核型复杂(≥3个异常)占73%,高度复杂(≥5个异常)占45%。
  • 最常见染色体异常为涉及MYC的易位(62%)、del17p(38%)、tri18(30%)、del13q(29%)、tri3(24%)、tri12(24%)和del8p(23%)。
  • 全外显子测序显示TP53、MYD88、BCOR、MYC、SF3B1、SETD2、CHD2、CXCR4和BCLAF1频繁突变。
  • 89%的B-PLL使用IGHV3或IGHV4亚组,79%显示IGHV基因显著突变。

关键数值与推荐

  • 3个细胞遗传学风险组:低危(无MYC异常)、中危(有MYC异常但无del17p)、高危(有MYC异常和del17p)(P = .0006)。
  • 体外药物反应分析显示,BCR或BCL2抑制剂联合OTX015(靶向MYC的BET抑制剂)与携带t(MYC)的B-PLL细胞活力显著降低相关。

临床怎么用

  • 对B-PLL患者进行细胞遗传学分析以评估MYC异常和del17p,用于风险分层。
  • 对于携带t(MYC)的B-PLL,可考虑靶向MYC的治疗策略(如BET抑制剂联合BCR或BCL2抑制剂)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

B-cell prolymphocytic leukemia (B-PLL) is a rare hematological disorder whose underlying oncogenic mechanisms are poorly understood. Our cytogenetic and molecular assessments of 34 patients with B-PLL revealed several disease-specific features and potential therapeutic targets. The karyotype was complex (≥3 abnormalities) in 73% of the patients and highly complex (≥5 abnormalities) in 45%. The most frequent chromosomal aberrations were translocations involving MYC [t(MYC)] (62%), deletion (del)17p (38%), trisomy (tri)18 (30%), del13q (29%), tri3 (24%), tri12 (24%), and del8p (23%). Twenty-six (76%) of the 34 patients exhibited an MYC aberration, resulting from mutually exclusive translocations or gains. Whole-exome sequencing revealed frequent mutations in TP53, MYD88, BCOR, MYC, SF3B1, SETD2, CHD2, CXCR4, and BCLAF1. The majority of B-PLL used the IGHV3 or IGHV4 subgroups (89%) and displayed significantly mutated IGHV genes (79%). We identified 3 distinct cytogenetic risk groups: low risk (no MYC aberration), intermediate risk (MYC aberration but no del17p), and high risk (MYC aberration and del17p) (P = .0006). In vitro drug response profiling revealed that the combination of a B-cell receptor or BCL2 inhibitor with OTX015 (a bromodomain and extra-terminal motif inhibitor targeting MYC) was associated with significantly lower viability of B-PLL cells harboring a t(MYC). We concluded that cytogenetic analysis is a useful diagnostic and prognostic tool in B-PLL. Targeting MYC may be a useful treatment option in this disease.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Chapiro E, Pramil E, Diop M, et al. Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53. Blood. 2019. PMID: 31527074. doi:10.1182/blood.2019001187

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。